An ai drug developer has generated $400m in an initial public offering. The company's work may involve partnerships to accelerate development of certain therapies, although details of its specific focus and collaborations are unclear. Research in the field appears to encompass a range of areas, including inflammatory and autoimmune disease therapeutics and next-gen adc development.